Emblaveo MDR Infections: Evaluating a New Solut...

By HEOR Staff Writer

November 18, 2025

Emblaveo Approved for MDR Gram-Negative Infections Emblaveo MDR infections pose a growing threat in Portugal, with the public assessment report evaluating Emblaveo (aztreonam + avib...
NICE NHS Prioritization: A Strategic Shift to Address Healthcare Challenges
Challenging the Narrative: Pharmaceutical Innovation Funding and Its Complex ...
NICE Endorses Darolutamide Prostate Cancer Treatment for Improved Patient Access
Rethinking Health Technology Assessment: Evolving Economic Evaluations for Fa...
Paving the Way for Digital Health Technologies: NICE’s Bold New Strateg...
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic ...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...
Rare Medications Coverage in the Netherlands: Price Reductions Required
Enhancing Benefit Assessments: Insights from IQWiG Real-World Data Report